The therapeutic community is excited with anticipation surrounding retatrutide, a innovative dual GIP and GLP-1 receptor that’s demonstrating significant efficacy in clinical trials for managing obesity. Unlike some existing weight loss treatments, retatrutide appears to offer a greater substantial decrease in body size and improve metabolic func